Clinical outcomes and prognostic factors in patients with multiple myeloma in South Tyrol: a retrospective single-center analysis

High-dose chemotherapy followed by autologous stem cell transplantation (HD-ASCT) as well as the introduction of novel agents (NA) significantly improved survival for patients with multiple myeloma (MM). A total of 150 unselected newly diagnosed MM patients treated at our institution from 1998 to 20...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of hematology 2020-05, Vol.99 (5), p.1031-1040
Hauptverfasser:	Mair, Maximilian, Straka, Christian, Buratti, Thomas, Tauber, Martina, Mitterer, Manfred, Fong, Dominic
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Agents - administration & dosage Autografts Clinical outcomes Disease-Free Survival Female Hematology Humans Italy Life Sciences & Biomedicine Male Medical prognosis Medicine Medicine & Public Health Middle Aged Multiple myeloma Multiple Myeloma - mortality Multiple Myeloma - therapy Oncology Original Article Retrospective Studies Science & Technology Stem Cell Transplantation Survival Rate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	High-dose chemotherapy followed by autologous stem cell transplantation (HD-ASCT) as well as the introduction of novel agents (NA) significantly improved survival for patients with multiple myeloma (MM). A total of 150 unselected newly diagnosed MM patients treated at our institution from 1998 to 2017 were retrospectively analyzed. Median age at diagnosis was 69 years (range 33–93 years) with a median follow-up of 48.6 months. The median overall survival (OS) for the entire cohort was 60.7 months (range 0.3–280.1). Patients who received frontline HD-ASCT ( p
ISSN:	0939-5555 1432-0584
DOI:	10.1007/s00277-020-03969-9